newsfilter
← Latest News
GlobeNewswire·

Acumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

NEWTON, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) (Acumen), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers